| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results fo... |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for ... |
| 21 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, the 2013 Incentive Compensation Plan was originally adopted by the Board in March 2013 and approved by the stockholders on June 13, 2013; the Amended and Restated 2013 Incentive Compensation Plan was adopted by the Board in Marc... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, May 13, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for it... |
| 17 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, March 17, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for ... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
SOLANA BEACH, CA, January 12, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced preliminary unaudite... |
| 05 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
As previously disclosed in the Quarterly Report on Form 10-Q of ClearPoint Neuro, Inc. (the “Company”) filed with the Securities and Exchange Commission on November 6, 2025 (the “Q3 2025 Form 10-Q”), the Company, CALW SA LLC, as purchase... |
| 20 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
Acquisition Will Enhance ClearPoint Neuro’s Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization |
| 06 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”), dated as of November [ ], 2025, is entered into by and among ClearPoint Neuro Inc., a Delaware corporation (“Purchaser”), Ignite Merger Sub, Inc., a Delaware corp... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, August 12, 2025 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for... |
| 17 Jun 2025 |
8-K: Entry into a Material Definitive Agreement
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
| 23 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The annual meeting of the stockholders of ClearPoint Neuro, Inc. (the “Company”) was held on May 21, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve the adoption of the ClearPoint Neuro, In... |
| 19 May 2025 |
8-K: Other Events
This Non-Employee Director Compensation Plan (this “Plan”) sets forth the compensation for non-employee members of the Board of Directors (the “Board”) of ClearPoint Neuro, Inc. (the “Company”). This Plan applies only to non-employee mem... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, May 13, 2025 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for it... |
| 12 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Note Purchase Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is made and dated as of May 12, 2025 (the “Effective Date”) among the Purchasers listed on Schedule 1.1 her... |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, February 26, 2025 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results f... |
| 07 Nov 2024 |
8-K: Entry into a Material Definitive Agreement
ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), ... |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SOLANA BEACH, CA, November 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results fo... |
| 26 Aug 2024 |
8-K: Regulation FD Disclosure
SOLANA BEACH, CA, August 26, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that on August 23, 20... |
Loading...